Nocdurna (Desmopressin)

Desmopressin is a synthetic analogue of the natural hormone vasopressin. It selectively binds to V2 receptors on the cells of the renal collecting ducts, stimulating a cascade that inserts aquaporin‑2 water channels into the duct lumen. This increases water permeability, allowing more water to be reabsorbed and decreasing urine volume.

The dose of Nocdurna is individualized by the prescribing clinician based on the patient’s age, weight, severity of the condition, renal function and response to therapy. No fixed regimen is provided here; the prescriber will adjust the dose to achieve the desired antidiuretic effect while monitoring safety parameters.

Safety data for desmopressin in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians are advised to discuss the uncertainty with patients and consider alternative therapies when appropriate.

To request Nocdurna, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nocdurna (desmopressin) is a selective V2‑receptor agonist, offering a more targeted antidiuretic effect than non‑selective vasopressin analogues. It has a longer duration of action and is available in a convenient sublingual form, which can improve adherence compared with injectable or nasal preparations of older agents.

Nocdurna should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original blister pack, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Nocdurna is taken sublingually. The tablet is placed under the tongue and allowed to dissolve completely without chewing or swallowing. Patients should avoid eating or drinking for at least 30 minutes after administration to ensure optimal absorption.

The most critical safety concerns are severe hyponatraemia and water intoxication, which can lead to seizures, cerebral edema, or coma. Patients should be educated to monitor fluid intake, report sudden headaches, nausea, confusion, or any signs of electrolyte imbalance promptly to their healthcare provider.

Nocdurna is contraindicated in patients with known hypersensitivity to desmopressin, severe renal impairment, uncontrolled hyponatraemia, or those taking other potent antidiuretic agents. Caution is also advised for individuals with chronic heart failure or liver disease where fluid balance is already compromised.